Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor

ORCID: 0000-0003-2611-5642

Publication year:
All
31 - 40 out of 231Page size: 10
Sort by: Title
  1. Published

    Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men

    Eelderink, C., Noort, M. W. J., Sozer, N., Koehorst, M., Holst, Jens Juul, Deacon, Carolyn F., Rehfeld, Jens Frederik, Poutanen, K., Vonk, R. J., Oudhuis, L. & Priebe, M. G., 2017, In: European Journal of Nutrition. 56, 3, p. 1063-1076 14 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men

    Lindgren, O., Mari, A., Deacon, Carolyn F., Carr, R. D., Winzell, M. S., Vikman, J. & Ahrén, B., 2009, In: Journal of Clinical Endocrinology and Metabolism. 94, 8, p. 2887-92 5 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Differential regional metabolism of glucagon in anesthetized pigs.

    Deacon, Carolyn F., Kelstrup, M., Trebbien, R., Klarskov, L., Olesen, M. & Holst, Jens Juul, 2003, In: American Journal of Physiology: Endocrinology and Metabolism. 285, 3, p. E552-60

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

    Deacon, Carolyn F., 2007, In: Expert Opinion on Investigational Drugs. 16, 4, p. 533-45 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

    Deacon, Carolyn F., 2020, In: Nature Reviews Endocrinology. 16, 11, p. 642-653

    Research output: Contribution to journal › Review › Research › peer-review

  6. Published

    Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.

    Deacon, Carolyn F. & Holst, Jens Juul, 2002, In: Biochemical and Biophysical Research Communications. 294, 1, p. 1-4 3 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

    Deacon, Carolyn F., Hughes, T. E. & Holst, Jens Juul, 1998, In: Diabetes. 47, p. 764-769

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

    Deacon, Carolyn F., Danielsen, P., Klarskov, L., Holst, Jens Juul & Olesen, M., 2001, In: Diabetes. 50, p. 1588-1597

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

    Deacon, Carolyn F. & Holst, Jens Juul, 2005, In: International Journal of Biochemistry & Cell Biology. 38, 5-6, p. 831-44 13 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

    Deacon, Carolyn F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O. & Holst, Jens Juul, 1998, In: Diabetologia. 41, p. 271-278

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 3 4 5 6 7 8 ...24 Next

ID: 9220